Eli Lilly and Novo Nordisk are preparing to take their rivalry to the next frontier of weight-loss medication: pills.
In this article
Eli Lilly
and Novo Nordisk
are preparing to take their rivalry to the next frontier of weight-loss medications: pills.
Both companies expect to launch oral obesity drugs in the U.S. next year, once regulators approve them. Daily pills could introduce more people to GLP-1s, the class of medicine that’s best known for weekly shots.
Eli Lilly's orforglipron could have a few advantages over a pill from Novo Nordisk, including a lack of dietary restrictions and…
Patients can already access the first GLP-1 obesity pill from Novo Nordisk, and a rival oral drug from Eli Lilly is slated for…
The approval gives Novo Nordisk a head start over chief rival Eli Lilly, which is racing to launch its own obesity pill.
Novo and Eli Lilly are both trying to shape the narrative of their rival pills, considered to be the start of the next phase of…
2026 is likely the year that two new oral weight loss drugs from Novo Nordisk and Eli Lilly will reach patients in the U.S.
Eli Lilly's pill, orforglipron, is one step closer to becoming the first new, needle-free alternative in the booming market for…
